Pharmafile Logo
Pharmafocus logo
Advanced Search

RA

Showing 15 posts of 32 posts found.

bms

European Commission approves new RA treatment from BMS

September 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis

Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …

News
Hospira image

Data supports switching to Hospira biosimilar for RA

June 10, 2015
Research and Development, Sales and Marketing EULAR, Hospira, Janssen, RA, brett wells, celltrion, inflectra, rome

Findings presented at EULAR this week from the first real-world study in patients with rheumatic diseases supports switching from J&J’s …

News
Orencia image

BMS backs rheumatoid arthritis prevention trial

March 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis

Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …

News
janssen image

Janssen abandons Simponi application

May 23, 2014
Sales and Marketing Europe, Janssen, RA, Simponi, rheumatoid arthritis

Janssen Biologics has withdrawn its application to add an intravenous (IV) form to the marketing authorisation of veteran rheumatoid arthritis …

News
Humira image

Humira drives AbbVie again

April 28, 2014
Sales and Marketing AbbVie, Abbott, Humira, RA

Rheumatoid arthritis treatment Humira has once more driven AbbVie, bringing in more than half the company’s sales in the first …

News
Vimovo image

AstraZeneca sells arthritis drug for $35 million

November 20, 2013
Sales and Marketing AstraZeneca, RA, arthritis, horizon, vimovo

AstraZeneca has sold rights to its arthritis treatment Vimovo to speciality pharma firm Horizon Pharma for $35 million.  AZ retains …

News
Ablynx image

AbbVie signs $840m RA deal

September 25, 2013
Sales and Marketing AbbVie, Ablynx, RA, alx

News
Orencia image

Orencia matches Humira

June 13, 2013
Sales and Marketing AbbVie, Abbott, Humira, Orencia, RA

Bristol-Myers Squibb is hoping its biologic Orencia can grab a little more of the rheumatoid arthritis market after demonstrating non-inferiority …

News
GSK image

GSK licences RA drug

June 5, 2013
Research and Development, Sales and Marketing GSK, RA, morphosys

GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …

News
astrazeneca image

AstraZeneca abandons late-stage RA drug

June 5, 2013
Research and Development, Sales and Marketing AstraZeneca, RA, Rigel

AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …

News

Pfizer’s Xeljanz rejected in Europe

April 28, 2013
Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis

Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …

News
Humira image

AbbVie guards Humira data

March 13, 2013
Sales and Marketing AbbVie, Abbott, Humira, RA, transparency

AbbVie has issued two injunctions against the European Medicines Agency to prevent the regulator revealing data about rheumatoid arthritis drug …

News
lilly image

Lilly abandons RA drug

February 8, 2013
Research and Development, Sales and Marketing RA, lilly, tabalumab

Lilly is abandoning its late-stage trial into investigational rheumatoid arthritis (RA) drug tabalumab but insists the move has nothing to …

News
Astrazeneca image

RA setbacks for AstraZeneca and Lilly

December 14, 2012
Research and Development, Sales and Marketing AstraZeneca, Humira, RA, lilly

AstraZeneca and Eli Lilly have both suffered setbacks in their attempts to push their respective investigational rheumatoid arthritis (RA) treatments …

News
Humira image

Humira continues to drive Abbott

October 22, 2012
Sales and Marketing AbVie, Abbott, Humira, RA

Abbott Laboratories’ rheumatoid arthritis drug Humira has once again shown its value to the company with a strong performance in …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024